REFERENCES
- L. E. Appel, W. J. Curatolo, S. M. Herbig, J. A. S. Nightingale, and A. G. Thombre (2000). Osmotic system for delivery of solid amorphous dispersions of drugs. European Patent EP1027888.
- R. Cortese, and F. Theeuwes (1982). Osmotic device with hydrogel driving member. U.S. Patent 4327725.
- D. Q. M. Craig. (2002). The mechanisms of drug release from solid dispersions in water-soluble polymers. Int. J. Pharm. 231:131–144.
- D. Ke, and G. Sun. (2004). The effect of reactive oxygen species on ethylene production induced by osmotic stress in etiolated mungbean seedling. Plant Growth Regul. 44:149–155.
- C. Leuner, and J. Dressman. (2000). Improving drug solubility for oral delivery using solid dispersions. Eur. J. Pharm. 50:47–60.
- Y. Ling, and B. Xu. (1993). Inhibition of phosphorylation of histone H1 and H3 induced by the 10-hydroxycamptothecin, DNA topoisomerase I inhibitor, in murine ascites hepatoma cells. Zhongguo Yao Li Xue Bao 14:546–550.
- L. Liu, J. Ku, G. Khang, B. Lee, J. M. Rhee, and H. B. Lee. (2000). Nifedipine controlled delivery by sandwiched osmotic tablet system. J. Control. Release 68:145–156.
- L. Liu, G. Khang, J. M. Rhee, and H. B. Lee. (2000). Monolithic osmotic tablet system for nifedipine delivery. J. Control. Release 67:309–322.
- E.-X. Lu, Z. Q. Jiang, Q. Z. Zhang, and X. G. Jiang. (2003). A water-insoluble drug monolithic osmotic tablet system utilizing gum Arabic as an osmotic, suspending and expanding agent. J. Control. Release 92:375–382.
- K. Okimoto, Y. Tokunaga, R. Ibuki, T. Irie, K. Uekama, R. A. Rajewski, and et al (2004). Applicability of (SBE)7m-β-CD in controlled-porosity osmotic pump tablets (OPTs). Int. J. Pharm. 286:81–88.
- A. Royce, S. Li, M. Weaver, and U. Shah. (2004). In vivo and in vitro evaluation of three controlled release principles of 6-N-cyclohexyl-2’-O-methyladenosine. J. Control. Release 97:79–90.
- Li Su, Z. Li, G. Zhong zhen, J. Zhan, L. Yu yan, and J. Wen qi. (2005). Absolute bioavailability of hydroxycamptothecin tablets in cancer patient. J. Clin. Pharmacol. 21:46–49.
- F. Theeuwes. (1975). Elementary osmotic pump. J. Pharm. Sci. 64:1987–1991.
- F. Theeuwes,and T. Higuchi (1975). Osmotic dispensing device with maximum and minimum sizes for the passageway. U.S. Patent 3916899.
- F. Theeuwes (1981). Novel drug delivery systems. In L. F. Prescott, and W. S. Nimmo (Ed.), Drug Absorption ( pp. 157–176). Balgowlah, Australia: ADIS Press.
- N. A. Urbanetz, and B. C. Lippold. (2005). Solid dispersions of nimodipine and polyethylene glycol 2000: Dissolution properties and physico-chemical characterization. Eur. J. Pharm. 59:107–118.
- R. K. Verma, B. Mishra, and S. Garg. (2000). Osmotically controlled oral drug delivery. Drug Dev. Ind. Pharm. 26:695–708.
- R. K. Verma, D. M. Krishna, and S. Garg. (2002). Formulation aspects in the development of osmotically controlled oral drug delivery systems. J. Control. Release 79:7–27.
- Y. Gan, W. Pan, M. Wei, and R. Zhang. (2002). Cyclodextrin complex osmotic tablet for glipizide delivery. Drug Dev. Ind. Pharm. 28:1015–1021.
- R. W. Zhang, Y. F. Li, Q. Y. Cai, T. P. Liu, and H. Sun. (1998). Preclinical pharmacology of the natural product anticancer agent 10-hydroxycamptothecin, an inhibitor of topoisomerase I. Cancer Chemother. Pharmacol. 41:257–267.